Drugs / FOLFIRINOX
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04130399 | Jul 2019 → Jan 2022 | pancreatic adenocarcinoma | Indiana University | Withdrawn | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06714604 | Oct 2023 → Dec 2032 expected | pancreatic adenocarcinoma | Sahlgrenska University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT05529940 | Apr 2023 → Dec 2024 overdue | pancreatic exocrine neoplasm | Seoul National University Hospital | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT04897854 Comparator | Apr 2021 → Apr 2024 | malignant pancreatic neoplasm | Academic Medical Center - University of Amsterdam | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Folfirinox | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04897854 ↗ |